person · Reporting owner

Gover Justin D.

Disclosed activity across 4 companies

Tapewire entity: 39300
SEC CIK: 0001754129

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
COMPASS Pathways plcCMPS · Entity 4567	Director	May 27, 2026	May 29, 2026
Design Therapeutics, Inc.DSGN · Entity 4991	Director	June 09, 2026	June 11, 2026
Xenon Pharmaceuticals Inc.XENE · Entity 2602	Director	June 01, 2026	June 04, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

COMPASS Pathways plc

Report date May 27, 2026 · Filed May 29, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.85 · Expires 2036-05-26	Direct	21,110	Reported balance After 2026-05-27 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-05-27 · Grant · Acquired 21,110 · Balance 21,110 F1: The shares underlying this option vest in full upon the earlier to occur of (i) the first anniversary of the date of grant or (ii) the date of COMPASS Pathways plc's Annual General Meeting of Shareholders in 2027. F2: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Filing footnotes · ownership attribution and instrument terms

F1: The shares underlying this option vest in full upon the earlier to occur of (i) the first anniversary of the date of grant or (ii) the date of COMPASS Pathways plc's Annual General Meeting of Shareholders in 2027.

F2: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Design Therapeutics, Inc.

Report date June 09, 2026 · Filed June 11, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.55 · Expires 2036-06-08	Direct	30,000	Reported balance After 2026-06-09 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-09 · Grant · Acquired 30,000 · Balance 30,000 F1: The shares subject to the option vest in equal monthly installments over 12 months following June 9, 2026 provided that the shares subject to the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to the option vest in equal monthly installments over 12 months following June 9, 2026 provided that the shares subject to the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders.

Xenon Pharmaceuticals Inc.

Report date June 01, 2026 · Filed June 04, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common SharesSEC Table I · non-derivative	Direct	2,645	Reported balance After 2026-06-01 transaction · row 1 1 source row Row 1 · 2026-06-01 · Exercise / conversion · Acquired 2,645 · Balance 2,645 F1: Represents Common Shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders.
Restricted Share UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2026-06-01 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-01 · Exercise / conversion · Disposed 2,645 · Balance 0 F1: Represents Common Shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders.
Restricted Share UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	1,593	Reported balance After 2026-06-03 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-06-03 · Grant · Acquired 1,593 · Balance 1,593 F3: Each RSU represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders.
Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $53.46 · Expires 2036-06-02	Direct	10,507	Reported balance After 2026-06-03 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-06-03 · Grant · Acquired 10,507 · Balance 10,507 F2: Vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders.

Filing footnotes · ownership attribution and instrument terms

F1: Represents Common Shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders.

F2: Vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders.

F3: Each RSU represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

GW PHARMACEUTICALS PLC

Report date May 05, 2021 · Filed May 07, 2021

Section 16 reporting ended · disclosed 2021-05-07. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	Reported balance After 2021-05-05 transaction · row 1 1 source row Row 1 · 2021-05-05 · Disposition to issuer · Disposed 222,773 · Balance 0 F1: On May 5, 2021, Jazz Pharmaceuticals Public Limited Company, a public limited company incorporated in the Republic of Ireland ("Jazz"), Jazz Pharmaceuticals UK Holdings Limited, a private limited company incorporated in England and Wales and an indirect wholly owned subsidiary of Jazz ("Bidco") and the DR Nominee (as defined in the Transaction Agreement) acquired all outstanding ordinary shares, par value British Pound Sterling 0.001 per share, of GW Pharmaceuticals plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement") (continued in footnote 2). F2: At the effective time of the Scheme of Arrangement, Scheme Shareholders (as defined in the Scheme of Arrangement) became entitled to receive for each Scheme Share (as defined in the Scheme of Arrangement) held by them an amount equal to $16.66 2/3 in cash plus 0.010030 ordinary shares, nominal value $0.0001 per share, of Jazz ("Jazz ordinary shares"). The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on March 15, 2021.
Ordinary SharesSEC Table I · non-derivative	IndirectBy Justin D. Gover 2020 Irrevocable Trust dated December 14, 2020	Reported balance After 2021-05-05 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2021-05-05 · Disposition to issuer · Disposed 456,048 · Balance 0 F1: On May 5, 2021, Jazz Pharmaceuticals Public Limited Company, a public limited company incorporated in the Republic of Ireland ("Jazz"), Jazz Pharmaceuticals UK Holdings Limited, a private limited company incorporated in England and Wales and an indirect wholly owned subsidiary of Jazz ("Bidco") and the DR Nominee (as defined in the Transaction Agreement) acquired all outstanding ordinary shares, par value British Pound Sterling 0.001 per share, of GW Pharmaceuticals plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement") (continued in footnote 2). F2: At the effective time of the Scheme of Arrangement, Scheme Shareholders (as defined in the Scheme of Arrangement) became entitled to receive for each Scheme Share (as defined in the Scheme of Arrangement) held by them an amount equal to $16.66 2/3 in cash plus 0.010030 ordinary shares, nominal value $0.0001 per share, of Jazz ("Jazz ordinary shares"). The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on March 15, 2021.
Ordinary SharesSEC Table I · non-derivative	IndirectBy the Gover Family Investment LLP	Reported balance After 2021-05-05 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2021-05-05 · Disposition to issuer · Disposed 1,867,308 · Balance 0 F1: On May 5, 2021, Jazz Pharmaceuticals Public Limited Company, a public limited company incorporated in the Republic of Ireland ("Jazz"), Jazz Pharmaceuticals UK Holdings Limited, a private limited company incorporated in England and Wales and an indirect wholly owned subsidiary of Jazz ("Bidco") and the DR Nominee (as defined in the Transaction Agreement) acquired all outstanding ordinary shares, par value British Pound Sterling 0.001 per share, of GW Pharmaceuticals plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement") (continued in footnote 2). F2: At the effective time of the Scheme of Arrangement, Scheme Shareholders (as defined in the Scheme of Arrangement) became entitled to receive for each Scheme Share (as defined in the Scheme of Arrangement) held by them an amount equal to $16.66 2/3 in cash plus 0.010030 ordinary shares, nominal value $0.0001 per share, of Jazz ("Jazz ordinary shares"). The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on March 15, 2021.
Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2022-03-15	Direct	Reported balance After 2021-05-05 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2021-05-05 · Disposition to issuer · Disposed 17,508 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration.
Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $10.61 · Expires 2025-06-24	Direct	Reported balance After 2021-05-05 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2021-05-05 · Disposition to issuer · Disposed 75,864 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration.
Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $3.72 · Expires 2026-02-15	Direct	Reported balance After 2021-05-05 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2021-05-05 · Disposition to issuer · Disposed 213,240 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration.
Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $9.81 · Expires 2027-01-06	Direct	Reported balance After 2021-05-05 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2021-05-05 · Disposition to issuer · Disposed 142,344 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration.
Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $9.61 · Expires 2028-02-26	Direct	Reported balance After 2021-05-05 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2021-05-05 · Disposition to issuer · Disposed 147,624 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration.
Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $14.33 · Expires 2029-03-01	Direct	Reported balance After 2021-05-05 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2021-05-05 · Disposition to issuer · Disposed 119,472 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration.
Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $14.65 · Expires 2029-06-14	Direct	Reported balance After 2021-05-05 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2021-05-05 · Disposition to issuer · Disposed 30,936 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration.
Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2021-05-05 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2021-05-05 · Disposition to issuer · Disposed 22,440 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5: These stock options were granted with automatic vesting on exercisable date.
Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2021-05-05 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2021-05-05 · Disposition to issuer · Disposed 34,008 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5: These stock options were granted with automatic vesting on exercisable date.
Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2021-05-05 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2021-05-05 · Disposition to issuer · Disposed 226,752 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5: These stock options were granted with automatic vesting on exercisable date.
Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2021-05-05 transaction · row 14 Instrument identity requires review; Table II rows are not merged. 1 source row Row 14 · 2021-05-05 · Disposition to issuer · Disposed 12,492 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5: These stock options were granted with automatic vesting on exercisable date.
Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2021-05-05 transaction · row 15 Instrument identity requires review; Table II rows are not merged. 1 source row Row 15 · 2021-05-05 · Disposition to issuer · Disposed 55,488 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5: These stock options were granted with automatic vesting on exercisable date.
Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2021-05-05 transaction · row 16 Instrument identity requires review; Table II rows are not merged. 1 source row Row 16 · 2021-05-05 · Disposition to issuer · Disposed 287,904 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5: These stock options were granted with automatic vesting on exercisable date.
Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2021-05-05 transaction · row 17 Instrument identity requires review; Table II rows are not merged. 1 source row Row 17 · 2021-05-05 · Disposition to issuer · Disposed 479,844 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5: These stock options were granted with automatic vesting on exercisable date.
Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2021-05-05 transaction · row 18 Instrument identity requires review; Table II rows are not merged. 1 source row Row 18 · 2021-05-05 · Disposition to issuer · Disposed 164,496 · Balance 0 F4: Pursuant to the Transaction Agreement, one-third of these share options vested and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration, and the remaining two-thirds were converted into an option to acquire Jazz ordinary shares (with any performance goals deemed fully satisfied), half of which will vest on March 2, 2022 and half of which will vest on March 2, 2023. F5: These stock options were granted with automatic vesting on exercisable date.
Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2021-05-05 transaction · row 19 Instrument identity requires review; Table II rows are not merged. 1 source row Row 19 · 2021-05-05 · Disposition to issuer · Disposed 263,184 · Balance 0 F4: Pursuant to the Transaction Agreement, one-third of these share options vested and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration, and the remaining two-thirds were converted into an option to acquire Jazz ordinary shares (with any performance goals deemed fully satisfied), half of which will vest on March 2, 2022 and half of which will vest on March 2, 2023. F5: These stock options were granted with automatic vesting on exercisable date.

Filing footnotes · ownership attribution and instrument terms

F1: On May 5, 2021, Jazz Pharmaceuticals Public Limited Company, a public limited company incorporated in the Republic of Ireland ("Jazz"), Jazz Pharmaceuticals UK Holdings Limited, a private limited company incorporated in England and Wales and an indirect wholly owned subsidiary of Jazz ("Bidco") and the DR Nominee (as defined in the Transaction Agreement) acquired all outstanding ordinary shares, par value British Pound Sterling 0.001 per share, of GW Pharmaceuticals plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement") (continued in footnote 2).

F2: At the effective time of the Scheme of Arrangement, Scheme Shareholders (as defined in the Scheme of Arrangement) became entitled to receive for each Scheme Share (as defined in the Scheme of Arrangement) held by them an amount equal to $16.66 2/3 in cash plus 0.010030 ordinary shares, nominal value $0.0001 per share, of Jazz ("Jazz ordinary shares"). The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on March 15, 2021.

F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration.

F4: Pursuant to the Transaction Agreement, one-third of these share options vested and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration, and the remaining two-thirds were converted into an option to acquire Jazz ordinary shares (with any performance goals deemed fully satisfied), half of which will vest on March 2, 2022 and half of which will vest on March 2, 2023.

F5: These stock options were granted with automatic vesting on exercisable date.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 09, 2026 Filed Jun 11, 2026 20:15 UTC	Design Therapeutics, Inc. DSGN · Entity 4991	GrantStock Option (right to buy) · Derivative	30,000	$0.00 Strike: $10.55	$0.00	Disclosure SEC source: 0001754129-26-000006 · form4-06112026_040607.xml · derivative · entry 1 Gover Justin D. · CIK 0001754129 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2036-06-08 F1 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over 12 months following June 9, 2026 provided that the shares subject to the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders. Read SEC document
June 03, 2026 Filed Jun 4, 2026 01:04 UTC	Xenon Pharmaceuticals Inc. XENE · Entity 2602	GrantRestricted Share Units · Derivative	1,593	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001193125-26-256124 · ownership.xml · derivative · entry 4 Gover Justin D. · CIK 0001754129 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,593 Underlying: Common Shares · 1,593 shares Expires not disclosed F3 · derivative.exercise_date: Each RSU represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders. F3 · derivative.expiration_date: Each RSU represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders. Read SEC document
June 03, 2026 Filed Jun 4, 2026 01:04 UTC	Xenon Pharmaceuticals Inc. XENE · Entity 2602	GrantShare Option (Right to Buy) · Derivative	10,507	$0.00 Strike: $53.46	$0.00	Disclosure SEC source: 0001193125-26-256124 · ownership.xml · derivative · entry 3 Gover Justin D. · CIK 0001754129 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,507 Underlying: Common Shares · 10,507 shares Expires 2036-06-02 F2 · derivative.exercise_date: Vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders. Read SEC document
June 01, 2026 Filed Jun 4, 2026 01:04 UTC	Xenon Pharmaceuticals Inc. XENE · Entity 2602	Exercise / conversionRestricted Share Units · Derivative	2,645	$0.00	$0.00	Disclosure SEC source: 0001193125-26-256124 · ownership.xml · derivative · entry 2 Gover Justin D. · CIK 0001754129 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 2,645 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents Common Shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders. F1 · derivative.exercise_date: Represents Common Shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders. F1 · derivative.expiration_date: Represents Common Shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders. Read SEC document
June 01, 2026 Filed Jun 4, 2026 01:04 UTC	Xenon Pharmaceuticals Inc. XENE · Entity 2602	Exercise / conversionCommon Shares	2,645	Not disclosed	Not disclosed	Disclosure SEC source: 0001193125-26-256124 · ownership.xml · nonDerivative · entry 1 Gover Justin D. · CIK 0001754129 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,645 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents Common Shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders. F1 · price: Represents Common Shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders. Read SEC document
May 27, 2026 Filed May 29, 2026 21:17 UTC	COMPASS Pathways plc CMPS · Entity 4567	GrantShare Option (Right to Buy) · Derivative	21,110	$0.00 Strike: $11.85	$0.00	Disclosure SEC source: 0001754129-26-000004 · wk-form4_1780089449.xml · derivative · entry 1 Gover Justin D. · CIK 0001754129 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,110 Underlying: Ordinary Shares · 21,110 shares Expires 2036-05-26 F1 · derivative.exercise_date: The shares underlying this option vest in full upon the earlier to occur of (i) the first anniversary of the date of grant or (ii) the date of COMPASS Pathways plc's Annual General Meeting of Shareholders in 2027. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
January 02, 2026 Filed Jan 5, 2026 21:10 UTC	Design Therapeutics, Inc. DSGN · Entity 4991	GrantStock option (right to buy) · Derivative	45,000	$0.00 Strike: $9.10	$0.00	Disclosure SEC source: 0001754129-26-000002 · form4-01052026_090117.xml · derivative · entry 1 Gover Justin D. · CIK 0001754129 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2036-01-01 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over 36 months following September 9, 2025. Read SEC document
September 09, 2025 Filed Sep 10, 2025 21:18 UTC	Design Therapeutics, Inc. DSGN · Entity 4991	GrantStock option (right to buy) · Derivative	15,833	$0.00 Strike: $6.64	$0.00	Disclosure SEC source: 0001415889-25-024109 · form4-09102025_090913.xml · derivative · entry 2 Gover Justin D. · CIK 0001754129 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,833 Underlying: Common Stock · 15,833 shares Expires 2035-09-08 F2 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over 12 months following September 9, 2025. Read SEC document
September 09, 2025 Filed Sep 10, 2025 21:18 UTC	Design Therapeutics, Inc. DSGN · Entity 4991	GrantStock option (right to buy) · Derivative	30,000	$0.00 Strike: $6.64	$0.00	Disclosure SEC source: 0001415889-25-024109 · form4-09102025_090913.xml · derivative · entry 1 Gover Justin D. · CIK 0001754129 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2035-09-08 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over 36 months following September 9, 2025. Read SEC document
July 29, 2025 Filed Jul 30, 2025 20:25 UTC	COMPASS Pathways plc CMPS · Entity 4567	GrantShare Option (Right to Buy) · Derivative	52,000	$0.00 Strike: $4.29	$0.00	Disclosure SEC source: 0001816590-25-000099 · wk-form4_1753907148.xml · derivative · entry 1 Gover Justin D. · CIK 0001754129 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,000 Underlying: Ordinary Shares · 52,000 shares Expires 2035-07-28 F1 · derivative.exercise_date: This option shall vest in 36 equal monthly installments over three years, with the first tranche vesting and becoming exercisable on August 29, 2025. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
June 05, 2025 Filed Jun 6, 2025 21:59 UTC	Xenon Pharmaceuticals Inc. XENE · Entity 2602	GrantRestricted Share Units · Derivative	2,645	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000950170-25-083325 · ownership.xml · derivative · entry 2 Gover Justin D. · CIK 0001754129 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,645 Underlying: Common Shares · 2,645 shares Expires not disclosed F2 · derivative.exercise_date: Each restricted share unit represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 4, 2026 or (ii) the day before the date of the issuer's 2026 annual meeting of shareholders. F2 · derivative.expiration_date: Each restricted share unit represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 4, 2026 or (ii) the day before the date of the issuer's 2026 annual meeting of shareholders. Read SEC document
June 05, 2025 Filed Jun 6, 2025 21:59 UTC	Xenon Pharmaceuticals Inc. XENE · Entity 2602	GrantShare Option (Right to Buy) · Derivative	17,012	$0.00 Strike: $30.73	$0.00	Disclosure SEC source: 0000950170-25-083325 · ownership.xml · derivative · entry 1 Gover Justin D. · CIK 0001754129 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,012 Underlying: Common Shares · 17,012 shares Expires 2035-06-04 F1 · derivative.exercise_date: Vesting 100% on the earlier of (i) June 4, 2026 or (ii) the day before the date of the issuer's 2026 annual meeting of shareholders. Read SEC document
June 05, 2024 Filed Jun 5, 2024 21:42 UTC	Xenon Pharmaceuticals Inc. XENE · Entity 2602	GrantStock Option (Right to Buy) · Derivative	15,542	$0.00 Strike: $38.16	$0.00	Disclosure SEC source: 0000950170-24-069466 · ownership.xml · derivative · entry 1 Gover Justin D. · CIK 0001754129 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,542 Underlying: Common Shares · 15,542 shares Expires 2034-06-04 F1 · derivative.exercise_date: Vesting 100% on the earlier of (i) June 4, 2025 or (ii) the day before the date of the issuer's 2025 annual meeting of shareholders. Read SEC document
August 10, 2023 Filed Aug 10, 2023 23:05 UTC	Xenon Pharmaceuticals Inc. XENE · Entity 2602	GrantStock Option (Right to Buy) · Derivative	28,000	$0.00 Strike: $38.39	$0.00	Disclosure SEC source: 0000950170-23-041534 · ownership.xml · derivative · entry 1 Gover Justin D. · CIK 0001754129 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,000 Underlying: Common Shares · 28,000 shares Expires 2033-08-09 F1 · derivative.exercise_date: One-third of the total shares subject to the Option shall vest on the first anniversary of August 8, 2023 (the "Start Date"), one-third on the second anniversary of the Start Date and the balance on the third anniversary of the Start Date. Read SEC document
May 05, 2021 Filed May 7, 2021 20:15 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Disposition to issuerShare Options · Derivative	263,184	Not disclosed Strike: $0.00	Not disclosed	Disclosure SEC source: 0000899243-21-018659 · doc4.xml · derivative · entry 19 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 263,184 shares Expires not disclosed F4 · price: Pursuant to the Transaction Agreement, one-third of these share options vested and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration, and the remaining two-thirds were converted into an option to acquire Jazz ordinary shares (with any performance goals deemed fully satisfied), half of which will vest on March 2, 2022 and half of which will vest on March 2, 2023. F4 · derivative.exercise_date: Pursuant to the Transaction Agreement, one-third of these share options vested and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration, and the remaining two-thirds were converted into an option to acquire Jazz ordinary shares (with any performance goals deemed fully satisfied), half of which will vest on March 2, 2022 and half of which will vest on March 2, 2023. F5 · derivative.expiration_date: These stock options were granted with automatic vesting on exercisable date. Read SEC document
May 05, 2021 Filed May 7, 2021 20:15 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Disposition to issuerShare Options · Derivative	164,496	Not disclosed Strike: $0.00	Not disclosed	Disclosure SEC source: 0000899243-21-018659 · doc4.xml · derivative · entry 18 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 164,496 shares Expires not disclosed F4 · price: Pursuant to the Transaction Agreement, one-third of these share options vested and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration, and the remaining two-thirds were converted into an option to acquire Jazz ordinary shares (with any performance goals deemed fully satisfied), half of which will vest on March 2, 2022 and half of which will vest on March 2, 2023. F4 · derivative.exercise_date: Pursuant to the Transaction Agreement, one-third of these share options vested and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration, and the remaining two-thirds were converted into an option to acquire Jazz ordinary shares (with any performance goals deemed fully satisfied), half of which will vest on March 2, 2022 and half of which will vest on March 2, 2023. F5 · derivative.expiration_date: These stock options were granted with automatic vesting on exercisable date. Read SEC document
May 05, 2021 Filed May 7, 2021 20:15 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Disposition to issuerShare Options · Derivative	479,844	Not disclosed Strike: $0.00	Not disclosed	Disclosure SEC source: 0000899243-21-018659 · doc4.xml · derivative · entry 17 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 479,844 shares Expires not disclosed F3 · price: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3 · derivative.exercise_date: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5 · derivative.expiration_date: These stock options were granted with automatic vesting on exercisable date. Read SEC document
May 05, 2021 Filed May 7, 2021 20:15 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Disposition to issuerShare Options · Derivative	287,904	Not disclosed Strike: $0.00	Not disclosed	Disclosure SEC source: 0000899243-21-018659 · doc4.xml · derivative · entry 16 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 287,904 shares Expires not disclosed F3 · price: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3 · derivative.exercise_date: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5 · derivative.expiration_date: These stock options were granted with automatic vesting on exercisable date. Read SEC document
May 05, 2021 Filed May 7, 2021 20:15 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Disposition to issuerShare Options · Derivative	55,488	Not disclosed Strike: $0.00	Not disclosed	Disclosure SEC source: 0000899243-21-018659 · doc4.xml · derivative · entry 15 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 55,488 shares Expires not disclosed F3 · price: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3 · derivative.exercise_date: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5 · derivative.expiration_date: These stock options were granted with automatic vesting on exercisable date. Read SEC document
May 05, 2021 Filed May 7, 2021 20:15 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Disposition to issuerShare Options · Derivative	12,492	Not disclosed Strike: $0.00	Not disclosed	Disclosure SEC source: 0000899243-21-018659 · doc4.xml · derivative · entry 14 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 12,492 shares Expires not disclosed F3 · price: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3 · derivative.exercise_date: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5 · derivative.expiration_date: These stock options were granted with automatic vesting on exercisable date. Read SEC document
May 05, 2021 Filed May 7, 2021 20:15 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Disposition to issuerShare Options · Derivative	226,752	Not disclosed Strike: $0.00	Not disclosed	Disclosure SEC source: 0000899243-21-018659 · doc4.xml · derivative · entry 13 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 226,752 shares Expires not disclosed F3 · price: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3 · derivative.exercise_date: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5 · derivative.expiration_date: These stock options were granted with automatic vesting on exercisable date. Read SEC document
May 05, 2021 Filed May 7, 2021 20:15 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Disposition to issuerShare Options · Derivative	34,008	Not disclosed Strike: $0.00	Not disclosed	Disclosure SEC source: 0000899243-21-018659 · doc4.xml · derivative · entry 12 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 34,008 shares Expires not disclosed F3 · price: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3 · derivative.exercise_date: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5 · derivative.expiration_date: These stock options were granted with automatic vesting on exercisable date. Read SEC document
May 05, 2021 Filed May 7, 2021 20:15 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Disposition to issuerShare Options · Derivative	22,440	Not disclosed Strike: $0.00	Not disclosed	Disclosure SEC source: 0000899243-21-018659 · doc4.xml · derivative · entry 11 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 22,440 shares Expires not disclosed F3 · price: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3 · derivative.exercise_date: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5 · derivative.expiration_date: These stock options were granted with automatic vesting on exercisable date. Read SEC document
May 05, 2021 Filed May 7, 2021 20:15 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Disposition to issuerShare Options · Derivative	30,936	Not disclosed Strike: $14.65	Not disclosed	Disclosure SEC source: 0000899243-21-018659 · doc4.xml · derivative · entry 10 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 30,936 shares Expires 2029-06-14 F3 · price: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3 · derivative.exercise_date: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. Read SEC document
May 05, 2021 Filed May 7, 2021 20:15 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Disposition to issuerShare Options · Derivative	119,472	Not disclosed Strike: $14.33	Not disclosed	Disclosure SEC source: 0000899243-21-018659 · doc4.xml · derivative · entry 9 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 119,472 shares Expires 2029-03-01 F3 · price: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3 · derivative.exercise_date: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. Read SEC document
May 05, 2021 Filed May 7, 2021 20:15 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Disposition to issuerShare Options · Derivative	147,624	Not disclosed Strike: $9.61	Not disclosed	Disclosure SEC source: 0000899243-21-018659 · doc4.xml · derivative · entry 8 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 147,624 shares Expires 2028-02-26 F3 · price: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3 · derivative.exercise_date: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. Read SEC document
May 05, 2021 Filed May 7, 2021 20:15 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Disposition to issuerShare Options · Derivative	142,344	Not disclosed Strike: $9.81	Not disclosed	Disclosure SEC source: 0000899243-21-018659 · doc4.xml · derivative · entry 7 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 142,344 shares Expires 2027-01-06 F3 · price: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3 · derivative.exercise_date: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. Read SEC document
May 05, 2021 Filed May 7, 2021 20:15 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Disposition to issuerShare Options · Derivative	213,240	Not disclosed Strike: $3.72	Not disclosed	Disclosure SEC source: 0000899243-21-018659 · doc4.xml · derivative · entry 6 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 213,240 shares Expires 2026-02-15 F3 · price: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3 · derivative.exercise_date: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. Read SEC document
May 05, 2021 Filed May 7, 2021 20:15 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Disposition to issuerShare Options · Derivative	75,864	Not disclosed Strike: $10.61	Not disclosed	Disclosure SEC source: 0000899243-21-018659 · doc4.xml · derivative · entry 5 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 75,864 shares Expires 2025-06-24 F3 · price: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3 · derivative.exercise_date: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. Read SEC document
May 05, 2021 Filed May 7, 2021 20:15 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Disposition to issuerShare Options · Derivative	17,508	Not disclosed Strike: $0.00	Not disclosed	Disclosure SEC source: 0000899243-21-018659 · doc4.xml · derivative · entry 4 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 17,508 shares Expires 2022-03-15 F3 · price: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3 · derivative.exercise_date: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. Read SEC document
May 05, 2021 Filed May 7, 2021 20:15 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Disposition to issuerOrdinary Shares	1,867,308	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-21-018659 · doc4.xml · nonDerivative · entry 3 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By the Gover Family Investment LLP Disclosed balance after: 0 F1 · price: On May 5, 2021, Jazz Pharmaceuticals Public Limited Company, a public limited company incorporated in the Republic of Ireland ("Jazz"), Jazz Pharmaceuticals UK Holdings Limited, a private limited company incorporated in England and Wales and an indirect wholly owned subsidiary of Jazz ("Bidco") and the DR Nominee (as defined in the Transaction Agreement) acquired all outstanding ordinary shares, par value British Pound Sterling 0.001 per share, of GW Pharmaceuticals plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement") (continued in footnote 2). F2 · price: At the effective time of the Scheme of Arrangement, Scheme Shareholders (as defined in the Scheme of Arrangement) became entitled to receive for each Scheme Share (as defined in the Scheme of Arrangement) held by them an amount equal to $16.66 2/3 in cash plus 0.010030 ordinary shares, nominal value $0.0001 per share, of Jazz ("Jazz ordinary shares"). The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on March 15, 2021. Read SEC document
May 05, 2021 Filed May 7, 2021 20:15 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Disposition to issuerOrdinary Shares	456,048	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-21-018659 · doc4.xml · nonDerivative · entry 2 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Justin D. Gover 2020 Irrevocable Trust dated December 14, 2020 Disclosed balance after: 0 F1 · price: On May 5, 2021, Jazz Pharmaceuticals Public Limited Company, a public limited company incorporated in the Republic of Ireland ("Jazz"), Jazz Pharmaceuticals UK Holdings Limited, a private limited company incorporated in England and Wales and an indirect wholly owned subsidiary of Jazz ("Bidco") and the DR Nominee (as defined in the Transaction Agreement) acquired all outstanding ordinary shares, par value British Pound Sterling 0.001 per share, of GW Pharmaceuticals plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement") (continued in footnote 2). F2 · price: At the effective time of the Scheme of Arrangement, Scheme Shareholders (as defined in the Scheme of Arrangement) became entitled to receive for each Scheme Share (as defined in the Scheme of Arrangement) held by them an amount equal to $16.66 2/3 in cash plus 0.010030 ordinary shares, nominal value $0.0001 per share, of Jazz ("Jazz ordinary shares"). The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on March 15, 2021. Read SEC document
May 05, 2021 Filed May 7, 2021 20:15 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Disposition to issuerOrdinary Shares	222,773	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-21-018659 · doc4.xml · nonDerivative · entry 1 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: On May 5, 2021, Jazz Pharmaceuticals Public Limited Company, a public limited company incorporated in the Republic of Ireland ("Jazz"), Jazz Pharmaceuticals UK Holdings Limited, a private limited company incorporated in England and Wales and an indirect wholly owned subsidiary of Jazz ("Bidco") and the DR Nominee (as defined in the Transaction Agreement) acquired all outstanding ordinary shares, par value British Pound Sterling 0.001 per share, of GW Pharmaceuticals plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement") (continued in footnote 2). F2 · price: At the effective time of the Scheme of Arrangement, Scheme Shareholders (as defined in the Scheme of Arrangement) became entitled to receive for each Scheme Share (as defined in the Scheme of Arrangement) held by them an amount equal to $16.66 2/3 in cash plus 0.010030 ordinary shares, nominal value $0.0001 per share, of Jazz ("Jazz ordinary shares"). The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on March 15, 2021. Read SEC document
March 19, 2021 Filed Mar 23, 2021 00:00 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	GiftOrdinary Shares	276,000	$0.00	$0.00	Disclosure SEC source: 0000899243-21-012950 · doc4.xml · nonDerivative · entry 1 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Gover Family Investment LLP Disclosed balance after: 1,867,308 F1 · kind: Reflects the gift of ordinary shares in the form of American Depositary Shares. Read SEC document
March 02, 2021 Filed Mar 5, 2021 02:04 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	GrantShare Options · Derivative	164,496	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000899243-21-010020 · doc4.xml · derivative · entry 2 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,496 Underlying: Ordinary Shares · 164,496 shares Expires not disclosed F3 · security: Granted pursuant to the Issuer's Long-Term Incentive Plan. F6 · security: The share numbers underlying options granted on February 22, 2021 and reported on the reporting person's form 4 filed on February 24, 2021 were amended as of March 2, 2021 and as reported in this form 4. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.41 U.S. Dollars as of February 22, 2021. F4 · derivative.exercise_date: These share options will vest in four equal annual installments beginning on February 22, 2022 and be automatically exercised upon vesting. F5 · derivative.exercise_date: Subject to accelerated vesting in connection with the closing of the transactions contemplated by the Transaction Agreement, dated as of February 3, 2021, by and among Jazz Pharmaceuticals UK Holdings Limited, Jazz Pharmaceuticals Public Limited Company and GW Pharmaceuticals plc. F4 · derivative.expiration_date: These share options will vest in four equal annual installments beginning on February 22, 2022 and be automatically exercised upon vesting. F5 · derivative.expiration_date: Subject to accelerated vesting in connection with the closing of the transactions contemplated by the Transaction Agreement, dated as of February 3, 2021, by and among Jazz Pharmaceuticals UK Holdings Limited, Jazz Pharmaceuticals Public Limited Company and GW Pharmaceuticals plc. Read SEC document
March 02, 2021 Filed Mar 5, 2021 02:04 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	GrantShare Options · Derivative	263,184	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000899243-21-010020 · doc4.xml · derivative · entry 1 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 263,184 Underlying: Ordinary Shares · 263,184 shares Expires not disclosed F1 · security: Granted pursuant to the Issuer's Long-Term Incentive Plan. These share options will vest and be automatically exercised on February 22, 2024 if certain performance conditions are satisfied. F6 · security: The share numbers underlying options granted on February 22, 2021 and reported on the reporting person's form 4 filed on February 24, 2021 were amended as of March 2, 2021 and as reported in this form 4. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.41 U.S. Dollars as of February 22, 2021. F1 · derivative.exercise_date: Granted pursuant to the Issuer's Long-Term Incentive Plan. These share options will vest and be automatically exercised on February 22, 2024 if certain performance conditions are satisfied. F5 · derivative.exercise_date: Subject to accelerated vesting in connection with the closing of the transactions contemplated by the Transaction Agreement, dated as of February 3, 2021, by and among Jazz Pharmaceuticals UK Holdings Limited, Jazz Pharmaceuticals Public Limited Company and GW Pharmaceuticals plc. F1 · derivative.expiration_date: Granted pursuant to the Issuer's Long-Term Incentive Plan. These share options will vest and be automatically exercised on February 22, 2024 if certain performance conditions are satisfied. F5 · derivative.expiration_date: Subject to accelerated vesting in connection with the closing of the transactions contemplated by the Transaction Agreement, dated as of February 3, 2021, by and among Jazz Pharmaceuticals UK Holdings Limited, Jazz Pharmaceuticals Public Limited Company and GW Pharmaceuticals plc. Read SEC document
March 01, 2021 Filed Mar 3, 2021 02:27 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Exercise / conversionShare Options · Derivative	17,004	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000899243-21-009215 · doc4.xml · derivative · entry 15 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 17,004 shares Expires 2021-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.39 U.S. Dollars as of March 1, 2021. F1 · kind: Exercise of share options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. Read SEC document
March 01, 2021 Filed Mar 3, 2021 02:27 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Tax withholdingOrdinary Shares	8,412	$17.85	$150,154.20	Disclosure SEC source: 0000899243-21-009215 · doc4.xml · nonDerivative · entry 10 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,773 F3 · kind: Withhold to cover vested RSU style share options. F4 · shares: Represented by ADS. F5 · price: The price reported is price per ordinary share converted from price per ADS. Read SEC document
March 01, 2021 Filed Mar 3, 2021 02:27 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Exercise / conversionOrdinary Shares	17,004	$0.00	$23.81	Disclosure SEC source: 0000899243-21-009215 · doc4.xml · nonDerivative · entry 9 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 231,185 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise of share options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. F2 · price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.39 U.S. Dollars as of February 26, 2021. Read SEC document
February 26, 2021 Filed Mar 3, 2021 02:27 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Exercise / conversionShare Options · Derivative	101,436	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000899243-21-009215 · doc4.xml · derivative · entry 14 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 101,436 shares Expires 2021-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.39 U.S. Dollars as of February 26, 2021. F1 · kind: Exercise of share options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. Read SEC document
February 26, 2021 Filed Mar 3, 2021 02:27 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Exercise / conversionShare Options · Derivative	24	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000899243-21-009215 · doc4.xml · derivative · entry 13 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 24 shares Expires 2021-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.39 U.S. Dollars as of February 26, 2021. F1 · kind: Exercise of share options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. Read SEC document
February 26, 2021 Filed Mar 3, 2021 02:27 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Exercise / conversionShare Options · Derivative	299,196	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000899243-21-009215 · doc4.xml · derivative · entry 12 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 299,196 shares Expires 2021-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.39 U.S. Dollars as of February 26, 2021. F1 · kind: Exercise of share options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. Read SEC document
February 26, 2021 Filed Mar 3, 2021 02:27 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Exercise / conversionShare Options · Derivative	22,440	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000899243-21-009215 · doc4.xml · derivative · entry 11 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 22,440 shares Expires 2021-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.39 U.S. Dollars as of February 26, 2021. F1 · kind: Exercise of share options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. Read SEC document
February 26, 2021 Filed Mar 3, 2021 02:27 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Tax withholdingOrdinary Shares	49,992	$17.90	$894,856.80	Disclosure SEC source: 0000899243-21-009215 · doc4.xml · nonDerivative · entry 8 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,181 F3 · kind: Withhold to cover vested RSU style share options. F4 · shares: Represented by ADS. F5 · price: The price reported is price per ordinary share converted from price per ADS. Read SEC document
February 26, 2021 Filed Mar 3, 2021 02:27 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Exercise / conversionOrdinary Shares	101,412	$0.00	$141.98	Disclosure SEC source: 0000899243-21-009215 · doc4.xml · nonDerivative · entry 7 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,173 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise of share options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. F2 · price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.39 U.S. Dollars as of February 26, 2021. Read SEC document
February 26, 2021 Filed Mar 3, 2021 02:27 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Tax withholdingOrdinary Shares	12	$17.90	$214.80	Disclosure SEC source: 0000899243-21-009215 · doc4.xml · nonDerivative · entry 6 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,761 F3 · kind: Withhold to cover vested RSU style share options. F4 · shares: Represented by ADS. F5 · price: The price reported is price per ordinary share converted from price per ADS. Read SEC document
February 26, 2021 Filed Mar 3, 2021 02:27 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Exercise / conversionOrdinary Shares	24	$0.00	$0.03	Disclosure SEC source: 0000899243-21-009215 · doc4.xml · nonDerivative · entry 5 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,773 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise of share options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. F2 · price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.39 U.S. Dollars as of February 26, 2021. Read SEC document
February 26, 2021 Filed Mar 3, 2021 02:27 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Tax withholdingOrdinary Shares	147,806	$17.90	$2,645,727.40	Disclosure SEC source: 0000899243-21-009215 · doc4.xml · nonDerivative · entry 4 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,749 F3 · kind: Withhold to cover vested RSU style share options. F4 · shares: Represented by ADS. F5 · price: The price reported is price per ordinary share converted from price per ADS. Read SEC document
February 26, 2021 Filed Mar 3, 2021 02:27 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Exercise / conversionOrdinary Shares	299,196	$0.00	$418.87	Disclosure SEC source: 0000899243-21-009215 · doc4.xml · nonDerivative · entry 3 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,555 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise of share options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. F2 · price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.39 U.S. Dollars as of February 26, 2021. Read SEC document
February 26, 2021 Filed Mar 3, 2021 02:27 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Tax withholdingOrdinary Shares	11,086	$17.90	$198,439.40	Disclosure SEC source: 0000899243-21-009215 · doc4.xml · nonDerivative · entry 2 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,359 F3 · kind: Withhold to cover vested RSU style share options. F4 · shares: Represented by ADS. F5 · price: The price reported is price per ordinary share converted from price per ADS. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.